NewAmsterdam Pharma develops oral therapies for cardiometabolic diseases and runs late-stage clinical programs around obicetrapib, a CETP inhibitor aimed at lowering LDL-cholesterol in high-risk cardiovascular disease patients. Its pipeline includes a fixed-dose combo of obicetrapib and ezetimibe in Phase 2 (ROSE2) and three Phase 3 trials (BROADWAY, BROOKLYN, and PREVAIL) to evaluate obicetrapib in HeFH, ASCVD, and as a cardiovascular outcomes trial. Founded in 2019 and based in Naarden, the Netherlands, the company focuses on transforming lipid management and cardiovascular risk reduction through targeted CETP inhibition.
Company Size
51-200
Company Stage
IPO
Headquarters
Naarden, Netherlands
Founded
2019
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?